ED Influenza Therapeutic Pilot Study: Oseltamivir vs. Peramivir

Exclusion Criteria

• •1. Does not speak and understand English (or English or Spanish)
• •2. Unable or unwilling to provide informed consent
• •3. Previously enrolled in the study during the current influenza season
• •4. Unable to take oral medication
• •5. Unable to comply with all planned study procedures including availability for follow-up and willingness to complete study diary and self-assessment
• •6. Use of neuraminidase inhibitors within the past seven days
• •7. Known allergic reaction to neuraminidase inhibitors
• •8. Pregnant or breastfeeding
• •9. End-stage renal disease, defined as 9a. Currently undergoing dialysis (either hemo or peritoneal); or 9b. Creatinine clearance (CrCl) of \<10 mL/min.
• •10. End-stage liver disease, as determined by the treating ED provider
• •11. Glucose-6-phosphate dehydrogenase (G6PD) deficiency by patient report
• •12. Immunodeficiency, defined as:
• •12a. Solid organ transplant patients receiving immunosuppression; 12b. Hematopoietic stem cell transplant patients within 12 months of transplant or with ongoing immunosuppression; 12c. Oncology patients who have had chemotherapy within the past 30 days; 12d. Current treatment with steroids equivalent to 10 mg of prednisone or more per day for greater than two weeks; 12e. Rheumatologic patients receiving immunosuppressive therapy; or 12f. HIV patients who meet one of the following criteria: 12fi. Have a cluster of differentiation 4 (CD4) cell count of \<200 cells/mm3 within the past 3 months ; 12fii. Not actively receiving highly active antiretroviral therapy (HAART); or 12fiii. Have an absolute lymphocyte count \<1.0 x 103 cells/μL conducted at the current ED visit